TY - JOUR
T1 - CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer
AU - Kawamura, Mikio
AU - Toiyama, Yuji
AU - Tanaka, Kouji
AU - Saigusa, Susumu
AU - Okugawa, Yoshinaga
AU - Hiro, Junichiro
AU - Uchida, Keiichi
AU - Mohri, Yasuhiko
AU - Inoue, Yasuhiro
AU - Kusunoki, Masato
PY - 2012/9
Y1 - 2012/9
N2 - Purpose: Serum CXCL5 levels in patients with colorectal cancer (CRC) were assessed to evaluate correlation with clinicopathologic features and prognosis. The effects of CXCL5 on CRC cells were also investigated in vitro. Methods: Based on cytokine array analysis, CXCL5 was identified as a novel prognostic serum marker. Serum levels of CXCL5 were assessed in 250 CRC patients and 33 normal volunteers by enzyme-linked immunosorbent assay (ELISA), and their relation to clinicopathologic findings and survival investigated. CXCL5 levels in CRC cell lines were also measured by ELISA, and CXCL5 and CXCR2 expression was evaluated by immunohistochemistry. To investigate the biological role of the CXCL5/CXCR2 axis, recombinant human CXCL5 and CXCR2 neutralisation antibodies were used for proliferation, migration and invasion assays. Results: Preoperative serum CXCL5 was significantly elevated in patients with CRC compared with healthy volunteers (p = 0.013). High serum CXCL5 was significantly associated with female sex (p = 0.0098) and liver metastasis (p = 0.0040). Univariate analysis correlated elevated CXCL5 with poor overall survival (p = 0.0002). Multivariate analysis showed that elevated CXCL5 was a significant and independent prognostic factor of survival in all CRC patients (p = 0.038). CRC cells secreted CXCL5, and administration of recombinant human CXCL5 promoted proliferation, migration and partial invasion. These effects were generally inhibited by CXCR2 neutralisation antibody. Conclusions: Preoperative serum CXCL5 could serve as a novel predictive marker for prognosis determination of CRC patients. CXCL5/CXCR2 axis might be associated with colorectal cancer progression.
AB - Purpose: Serum CXCL5 levels in patients with colorectal cancer (CRC) were assessed to evaluate correlation with clinicopathologic features and prognosis. The effects of CXCL5 on CRC cells were also investigated in vitro. Methods: Based on cytokine array analysis, CXCL5 was identified as a novel prognostic serum marker. Serum levels of CXCL5 were assessed in 250 CRC patients and 33 normal volunteers by enzyme-linked immunosorbent assay (ELISA), and their relation to clinicopathologic findings and survival investigated. CXCL5 levels in CRC cell lines were also measured by ELISA, and CXCL5 and CXCR2 expression was evaluated by immunohistochemistry. To investigate the biological role of the CXCL5/CXCR2 axis, recombinant human CXCL5 and CXCR2 neutralisation antibodies were used for proliferation, migration and invasion assays. Results: Preoperative serum CXCL5 was significantly elevated in patients with CRC compared with healthy volunteers (p = 0.013). High serum CXCL5 was significantly associated with female sex (p = 0.0098) and liver metastasis (p = 0.0040). Univariate analysis correlated elevated CXCL5 with poor overall survival (p = 0.0002). Multivariate analysis showed that elevated CXCL5 was a significant and independent prognostic factor of survival in all CRC patients (p = 0.038). CRC cells secreted CXCL5, and administration of recombinant human CXCL5 promoted proliferation, migration and partial invasion. These effects were generally inhibited by CXCR2 neutralisation antibody. Conclusions: Preoperative serum CXCL5 could serve as a novel predictive marker for prognosis determination of CRC patients. CXCL5/CXCR2 axis might be associated with colorectal cancer progression.
UR - http://www.scopus.com/inward/record.url?scp=84865502454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865502454&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2011.11.032
DO - 10.1016/j.ejca.2011.11.032
M3 - Article
C2 - 22197219
AN - SCOPUS:84865502454
SN - 0959-8049
VL - 48
SP - 2244
EP - 2251
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 14
ER -
